MYCN and Merkel cell skin cancer: Upon pyrvinium treatment, the predicted protein activity of several MCC master regulators, including p53, MYCN, SMADs, and SOX11, exhibited an opposite trend to that previously reported during MCC development (Figure 5B) (9, 20, 58–61).